- Home
- SLI vs CSTL Comparison
SLI vs CSTL Comparison
Compare SLI & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLI | CSTL |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.8M | 661.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SLI | CSTL |
|---|---|---|
| Price | $4.95 | $38.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $5.25 | ★ $40.67 |
| AVG Volume (30 Days) | ★ 3.4M | 461.5K |
| Earning Date | 11-10-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $343,530,000.00 |
| Revenue This Year | N/A | $1.69 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.15 |
| 52 Week Low | $1.08 | $14.59 |
| 52 Week High | $6.40 | $40.61 |
Technical Indicators
Market Signals| Indicator | SLI | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 64.59 | 68.66 |
| Support Level | $4.45 | $36.63 |
| Resistance Level | $4.93 | $40.54 |
| Average True Range (ATR) | 0.30 | 1.31 |
| MACD | 0.05 | -0.50 |
| Stochastic Oscillator | 86.35 | 53.39 |
Price Performance
Historical ComparisonAbout SLI Standard Lithium Ltd.
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company is focused on the exploration and development of the Arkansas Lithium Project, which is located in south-central Arkansas. Its other projects comprise the Lanxess Project, and Bristol Dry Lake Project.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.